Investigating how fibroblasts contribute to lung scarring in pulmonary fibrosis
Fibroblast Biology and Pulmonary Fibrosis
This study is looking at how a protein called Anoctamin-1 affects certain cells that cause scarring in the lungs of people with idiopathic pulmonary fibrosis (IPF), to help find new ways to treat this tough lung disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10661596 on NIH RePORTER |
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a serious lung disease characterized by progressive scarring that impairs lung function. The study aims to understand the role of a specific protein, Anoctamin-1 (ANO1), in the activation of fibroblasts, which are cells that contribute to the scarring process. By examining how TGF-β, a key cytokine, influences fibroblast behavior, the research seeks to uncover mechanisms that lead to the worsening of lung fibrosis. Patients may benefit from insights gained into potential new therapeutic targets for treating this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis.
Not a fit: Patients with other forms of lung disease unrelated to fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or reverse lung scarring in patients with pulmonary fibrosis.
How similar studies have performed: Previous research has shown promising results in targeting fibroblast activation in other fibrotic diseases, suggesting potential for success in this area as well.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Dulin, Nickolai O — University of Chicago
- Study coordinator: Dulin, Nickolai O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.